TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02422381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Investigational drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard care drug.
Study: NCT01711086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerolizer Followed by Inspiromatic
Description: Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiromatic followed by Aerolizer
Description: Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
Study: NCT02144675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choline magnesium trisalicylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01813019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: mGluR5 antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT04003597

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual-salt diet
Description: Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduced-salt diet
Description: Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (\<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
Study: NCT03737461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic BM-MSCs Injection
Description: Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
Study: NCT03074734

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to secondhand tobacco smoke
Description: The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
Study: NCT04694833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor and cognitive virtual reality-based assessments
Description: Motor and cognitive testing in virtual reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor and cognitive virtual reality-based assessments
Description: Motor and cognitive testing in virtual reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor and cognitive virtual reality-based serious games
Description: Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor and cognitive virtual reality-based serious games
Description: Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
Study: NCT00374777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem MR
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem MR
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrazepam
Description: oral
Study: NCT03493945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPV-Brachyury
Description: FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPV-Brachyury
Description: FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
Study: NCT00374777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT06410105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR ALIGNERS
Description: The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR ALIGNERS
Description: The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm
Study: NCT03675659

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intra-articular injection
Description: intra-articular injection with magnesium sulfate with four injections at weekly intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular injection
Description: intra-articular injection with magnesium sulfate with four injections at weekly intervals
Study: NCT01391117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo.
Description: panel 1: 2 participants receive placebo at a q24h regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo.
Description: panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128.
Description: panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo.
Description: panel 2, arm 2: 2 participants receive placebo at a q24h regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128
Description: panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128.
Description: panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128
Description: panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128.
Description: panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
Study: NCT03493945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 600 mg orally twice daily (1200 MG total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 600 mg orally twice daily (1200 MG total)
Study: NCT01391117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo.
Description: panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
Study: NCT02678611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Basis 250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Basis 500

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02705417

Intervention type: PROCEDURE
Intervention: preoperative color Doppler ultrasonographic vascular mapping
Description: Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
Study: NCT05868798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammonia Inhalant
Description: For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
Study: NCT01193556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade TnA
Description: The PEAK PlasmaBlade will be used for the tonsillectomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: Traditional electrosurgery for the tonsillectomy.
Study: NCT02705417

Intervention type: PROCEDURE
Intervention: physical examination
Description: Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.

Intervention type: PROCEDURE
Intervention: physical examination
Description: Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
Study: NCT02323191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
Study: NCT02705417

Intervention type: PROCEDURE
Intervention: medical history
Description: medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease

Intervention type: PROCEDURE
Intervention: medical history
Description: medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease

Intervention type: PROCEDURE
Intervention: native arteriovenous fistula construction
Description: surgigal creation of native arterial and venous anastomoses
Study: NCT04897542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 NODAGA-JR11
Description: Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
Study: NCT02705417

Intervention type: PROCEDURE
Intervention: native arteriovenous fistula construction
Description: surgigal creation of native arterial and venous anastomoses

Intervention type: PROCEDURE
Intervention: arteriovenous graft placement
Description: surgical placement of arteriovenous graft

Intervention type: PROCEDURE
Intervention: arteriovenous graft placement
Description: surgical placement of arteriovenous graft
Study: NCT01689922

Intervention type: OTHER
Intervention: AlterG
Description: All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity

Intervention type: OTHER
Intervention: AlterG
Description: All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
Study: NCT01062022

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS-CI
Description: Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
Study: NCT01167946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone sodium succinate
Description: Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone sodium succinate
Description: Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone sodium succinate
Description: Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
Study: NCT03145142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Cord Clamping
Description: At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
Study: NCT02638558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written + oral explanation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written explanation
Study: NCT04273464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brava-group
Description: Breast reconstruction by external tissue expansion and multiple fat transplantations(Brava group); Breast reconstruction with microsurgical DIEP-flap transfer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP-group
Description: Microsurgical reconstruction by DIEPO method
Study: NCT04558476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: 2 units of convalescent plasma

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Gold Standards
Study: NCT02690545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATLCAR.CD30 cells
Description: For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10\^8 cells/m\^2 and 2x10\^8 cells/m\^2. Phase II patients will receive the dose level decided upon in Phase I.
Study: NCT00780962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Description: Experimental:~* Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~* After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: Placebo:~* Before CT: 500 cc 0.9% Sodium-chloride~* After CT: NS at 67 cc/hour for up to 24 hours.
Study: NCT03755063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy apps
Description: Speech therapy apps loaded on tablets
Study: NCT01563250

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point of Care testing
Description: The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well.
Study: NCT03286140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early endovenous ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed endovenous intervention
Study: NCT01192594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in all modules including MAPP Recovery Model
Description: 50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training in all modules except MAPP Recovery Model
Description: 50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
Study: NCT03280355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing training
Description: Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Training
Description: Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres.
Study: NCT05016102

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise type
Description: Aerobic exercise and Resistance exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise type
Description: Aerobic exercise and Resistance exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise type
Description: Aerobic exercise and Resistance exercise
Study: NCT04606238

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: Oncologists and patients will use the decision aid in the same situation (change of treatment needs to be discussed with the patient - either because of disease progression or treatment toxicity or other reasons (e.g. change of care setting).
Study: NCT01313572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apadenoson SPECT-MPI
Description: Apadenoson single bolus IV injection 100 or 150 ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apadenoson SPECT-MPI
Description: Apadenoson single bolus IV injection 100 or 150 ug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine SPECT-MPI
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine SPECT-MPI
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute